All Eyes Are on Pfizer As Speculation Brews For Next Potential M&A

Published: Aug 07, 2017

As promised, Pfizer Inc (PFE) reported quarterly earnings during pre-market, but the anticipated release failed to impress after the pharmaceutical company didn't maintain expectations.

Revenue missed Wall Street projections, dipping 2% from $13.15 billion to $12.9 billion. Pfizer fell 0.86% in Monday morning trading to $33.35 a share.

"Every time I see the Pfizer quarter I recognize why they needed to do the Allergan [plc] (AGN) deal," said Jim Cramer, TheStreet's founder and portfolio manager of Action Alerts PLUS Charitable Trust.

Back to news